Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk

Table 2 Multivariable OR of colorectal cancer associated with statin and NSAIDs use

	Cases n (%)	Controls n (%)	OR1	95% CI1	OR2	95% CI2
NSAIDS
Never	462 (71.9)	837 (63.6)	1.00	Reference	1.00	Reference
Ever	181 (28.1)	480 (36.4)	0.69	0.55-0.86	0.70	0.56-0.88
Former	41 (6.4)	109 (8.3)	0.74	0.50-1.11	0.77	0.51-1.15
Current	140 (21.8)	371 (28.2)	0.68	0.53-0.86	0.68	0.53-0.88
Duration (yr)
< 1	8 (1.2)	25 (1.9)	0.71	0.30-1.65	0.71	0.30-1.69
1-4	85 (13.2)	233 (17.7)	0.70	0.52-0.93	0.70	0.52-0.94
≥ 5	88 (13.7)	222 (16.9)	0.68	0.51-0.92	0.71	0.52-0.96
Statins
Never use	453 (92.6)	1114 (93.2)	1.00	Reference	1.00	Reference
Ever use	36 (7.4)	81 (6.8)	1.03	0.66-1.60	1.17	0.74-1.85
Former	4 (0.8)	9 (0.8)	1.63	0.49-5.44	1.93	0.56-6.06
Current	32 (6.5)	72 (6.0)	0.97	0.60-1.55	1.09	0.67-1.78
Duration (yr)
< 3	17 (3.5)	41 (3.4)	0.96	0.51-1.80	1.07	0.56-2.03
≥ 3	19 (3.9)	40 (3.3)	1.10	0.60-2.00	1.27	0.68-2.38
Type
Lipophilic use	30 (6.1)	63 (5.3)	1.04	0.64-1.70	1.20	0.72-2.00
Hydrophilic use	7 (1.4)	20 (1.7)	1.06	0.43-2.63	1.10	0.44-2.77

¹Adjusted for age and reference year.

²Adjusted for age, reference year, education, post menopausal hormone use, first degree family history of colorectal cancers, body mass index, history of colorectal cancer endoscopic screening, and smoking.